A phase II trial of FOLFIRI combined with hyperthermia as second-line therapy of unresectable colon cancer with liver metastases
- Conditions
- Colon cancer patients with liver metastases who had been treated by FOLFOX as first-line therapy
- Registration Number
- JPRN-UMIN000001998
- Lead Sponsor
- Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Not provided
1.Patients who has received blood transfusion, blood products, and medicine made of blood formation factor within seven days of registration. 2.Medical history of severe hypersensitivity. 3.Massive ascites, pleural or pericardial effusin that required drainage. 4.With active infection. 5.With brain metastasis 6.With active double cancer. 7.Presence of uncontrolled hypertension. 8.Presence of uncontrolled diabetes. 9.Presence of unstable angina, myocardial infarction within three months. 10.Active gastrtrointestinal bleeding. 11.With intestinal paralysis, intestinal obstruction. 12.With diarrhea. 13.Patients receiving Atazanabil. 14.Pregnant or nursing women, men or women who like be pregnant. 15.Inappropriate patients for this study judged by the physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Time to treatment failure, Overall survival, Safety